Choice of lipid-regulating drugs.
D001053:Apolipoproteins / Q000097:blood; D001161:Arteriosclerosis / Q000209:etiology; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000517:prevention & control; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D011345:Fenofibrate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005395:Fish Oils / Q000627:therapeutic use; D015248:Gemfibrozil / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D009135:Muscular Diseases / Q000139:chemically induced; D009525:Niacin / Q000009:adverse effects / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
D001053:Apolipoproteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D005395:Fish Oils; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D014280:Triglycerides; D009525:Niacin; C006012:fenofibric acid; D015248:Gemfibrozil; D011345:Fenofibrate